Company intelligence
Lōkahi Therapeutics
Opportunity. Empathy. Balance.
About Lōkahi Therapeutics
Lōkahi Therapeutics transforms human insight into breakthrough therapies. We combine rigorous science, clinical judgment, and human empathy to develop novel therapies for unmet medical needs. Our lead program — Apitox — is a non-narcotic, honey-bee-venom–derived therapeutic being developed for inflammation and pain (including osteoarthritis). What sets us apart is our philosophy of “actual intelligence” (ai²) — integrating real-world clinical insight with cross-disciplinary expertise to unlock under-recognized assets, navigate regulatory and payer pathways, and anchor development around patient and physician needs, not hype.
Verified activity
Signals from Lōkahi Therapeutics
2 published signals
Strategy & Corporate Development
Lōkahi Therapeutics expanded its AI² platform into three business divisions spanning 13 universities, more than 45 therapeutic asset evaluations, and three dedicated business divisions.
Reported by Lōkahi Therapeutics
Presence & Recognition
Lōkahi Therapeutics welcomed Fowler College of Business at San Diego State University to the AI² network to expand asset origination capabilities and provide students with hands-on experience evaluating biopharmaceutical opportunities.
Reported by Lōkahi Therapeutics